2026-08-29T09:25:19Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/252102024-11-28T15:13:08Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Perez, Marco author Peinado-Serrano, Javier author Garcia-Heredia, Jose Manuel author Felipe-Abrio, Irene author Tous, Cristina author Ferrer, Irene author Martin-Broto, Javier author Saez, Carmen author Carnero, Amancio author Perez, Marco author Peinado-Serrano, Javier author Garcia-Heredia, Jose Manuel author Felipe-Abrio, Irene author Tous, Cristina author Ferrer, Irene author Martin-Broto, Javier author Saez, Carmen author Carnero, Amancio author 2016 Sarcomas are malignant tumors accounting for a high percentage of cancer morbidity and mortality in children and young adults. Surgery and radiation therapy are the accepted treatments for most sarcomas; however, patients with metastatic disease are treated with systemic chemotherapy. Many tumors display marginal levels of chemoresponsiveness, and new treatment approaches are needed. MAP17 is a small non-glycosylated membrane protein overexpressed in carcinomas. The levels of MAP17 could be used as a prognostic marker to predict the response to bortezomib in hematological malignancies and in breast tumors. Therefore, we analyzed the expression of this oncogene in sarcomas and its relationship with clinico-pathological features, as well as tested whether it can be used as a new biomarker to predict the therapeutic response to bortezomib and new therapies for sarcomas. We found that the levels of MAP17 were related to clinical features and poor survival in a cohort of 69 patients with different sarcoma types, not being restricted to any special subtype of tumor. MAP17 expression is associated with poor overall survival (p 10.18632/oncotarget.11475 1949-2553 Oncotarget http://hdl.handle.net/10668/10392 27563810 https://hdl.handle.net/20.500.12105/25210 MAP17 Biomarker Bortezomib Sarcomas PDX Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1)